• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga Pro's Top 5 Stocks To Watch For Thursday, Dec. 23, 2021 (Happy Holidays! Edition): NVAX, CROX, ADTH, KXIN, ALLK

    12/23/21 8:00:06 AM ET
    $ALLK
    $CROX
    $KXIN
    $MACQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Shoe Manufacturing
    Consumer Discretionary
    Get the next $ALLK alert in real time by email

    Today's 5 Stock Ideas (Happy Holidays! Edition):

    • Novavax (NVAX) - A play on another COVID-19 vaccine manufacturer. On Wednesday, study results showed the company's two-dose regimen of showed cross-reactive immune responses against Omicron and other variants.

    • Crocs (CROX) - The company announced the purchase of shoe company HEYDUDE for $2.5 billion.

    • AdTheorant (ADTH) - Will begin trading on the Nasdaq Thursday. The company announced the completion of its special purpose acquisition corporation (SPAC) merger with MCAP Acquisition.

    • Kaixin Auto Holdings (KXIN) - Shares were up 10% following news of an order for 10,000 customized electric trucks, valued at about $250 million.

    • Allakos (ALLK) - One of the most-discussed stocks in the Benzinga Pro chat Wednesday.

    The Benzinga newsdesk wants to wish our readers and community a very happy holiday over the next couple weeks! Here's to making even more money in the markets in 2022! 🤑

    A reminder the US stock market will be closed on Friday, Dec. 24 to observe the Christmas holiday on Saturday.

    The US stock market will not be closed next week for the New Year's holiday.

    Get the next $ALLK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK
    $CROX
    $KXIN
    $MACQ

    CompanyDatePrice TargetRatingAnalyst
    Crocs Inc.
    $CROX
    4/14/2026$135.00Neutral → Buy
    Seaport Research Partners
    Crocs Inc.
    $CROX
    3/10/2026Neutral
    BTIG Research
    Crocs Inc.
    $CROX
    2/13/2026$100.00 → $130.00Buy
    Monness Crespi & Hardt
    Crocs Inc.
    $CROX
    1/22/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Crocs Inc.
    $CROX
    1/7/2026$100.00Outperform → Neutral
    Robert W. Baird
    Crocs Inc.
    $CROX
    10/31/2025$92.00 → $100.00Buy
    Monness Crespi & Hardt
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Crocs Inc.
    $CROX
    9/22/2025$75.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ALLK
    $CROX
    $KXIN
    $MACQ
    SEC Filings

    View All

    SEC Form DEFA14A filed by Crocs Inc.

    DEFA14A - Crocs, Inc. (0001334036) (Filer)

    4/23/26 4:17:21 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form DEF 14A filed by Crocs Inc.

    DEF 14A - Crocs, Inc. (0001334036) (Filer)

    4/23/26 4:15:57 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form 6-K filed by Kaixin Holdings

    6-K - Kaixin Holdings (0001713539) (Filer)

    4/10/26 4:13:02 PM ET
    $KXIN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Replogle John B bought $223,500 worth of shares (3,000 units at $74.50), increasing direct ownership by 19% to 18,417 units (SEC Form 4)

    4 - Crocs, Inc. (0001334036) (Issuer)

    11/12/25 5:05:25 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    EVP, Chief Financial Officer Healy Susan L. bought $153,120 worth of shares (2,000 units at $76.56), increasing direct ownership by 4% to 50,078 units (SEC Form 4)

    4 - Crocs, Inc. (0001334036) (Issuer)

    8/14/25 6:39:34 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Director Replogle John B bought $250,084 worth of shares (3,261 units at $76.69), increasing direct ownership by 27% to 15,417 units (SEC Form 4)

    4 - Crocs, Inc. (0001334036) (Issuer)

    8/13/25 8:53:15 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crocs, Inc. Announces Conference Call to Review First Quarter 2026 Earnings Results

    BROOMFIELD, Colo., April 9, 2026 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX) announced today that on Thursday, April 30, 2026, at 8:30 am ET, it will host a conference call to discuss the results of its first quarter ended March 31, 2026.To receive conference call details, please register at the Investor Relations section of the Crocs website, investors.crocs.com. The webcast will also be available live and on replay through April 30, 2027 at this site.About Crocs, Inc.: Crocs, Inc. (NASDAQ:CROX), headquartered in Broomfield, Colorado, is a world leader in innovative casual footwear for all, combining comfort and style with a value that consumers know and love. The Company's brands include Cro

    4/9/26 7:30:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kaixin Holdings Announces Share Consolidation

    BEIJING, March 11, 2026 (GLOBE NEWSWIRE) -- Kaixin Holdings ("Kaixin" or the "Company") (NASDAQ:KXIN) announced that it will effect a share consolidation of its ordinary shares, par value $1.35 each, at a ratio of 1-for-15, with a post-share consolidation par value $20.25 each, effective on March 13, 2026 (the "Share Consolidation"). The Company's class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on March 13, 2026. Upon the market opening on March 13, 2026, the Company's class A ordinary shares will continue to be traded on The Nasdaq Capital Market under the symbol "KXIN" with the new CUSIP number G5223X175. As a result

    3/11/26 7:30:00 AM ET
    $KXIN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Walker Robert Edward

    4 - NOVAVAX INC (0001000694) (Issuer)

    4/16/26 6:13:00 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Walker Robert Edward

    3 - NOVAVAX INC (0001000694) (Issuer)

    4/16/26 5:40:20 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Reagan Patraic

    4 - Crocs, Inc. (0001334036) (Issuer)

    3/24/26 4:19:36 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crocs upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded Crocs from Neutral to Buy and set a new price target of $135.00

    4/14/26 8:12:23 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    BTIG Research initiated coverage on Crocs

    BTIG Research initiated coverage of Crocs with a rating of Neutral

    3/10/26 8:40:26 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Monness Crespi & Hardt reiterated coverage on Crocs with a new price target

    Monness Crespi & Hardt reiterated coverage of Crocs with a rating of Buy and set a new price target of $130.00 from $100.00 previously

    2/13/26 7:57:52 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Crocs, Inc. Appoints Executive Vice President and Chief Financial Officer Patraic Reagan; Reaffirms Third Quarter Guidance

    BROOMFIELD, Colo., Aug. 29, 2025 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX), a global leader in innovative casual footwear for all, today announced the appointment of Patraic Reagan as the Executive Vice President and Chief Financial Officer of Crocs, Inc, effective September 22, 2025. Mr. Reagan will succeed Susan Healy, who tendered her resignation on August 28, 2025, effective immediately. With approximately three decades of financial and operational leadership experience at prominent global consumer companies, Mr. Reagan will join the executive leadership team and will report directly to Andrew Rees, Chief Executive Officer. Most recently, Mr. Reagan served as the Chief Financial Officer

    8/29/25 7:30:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Crocs, Inc. Appoints Terence Reilly to Chief Brand Officer Role

    BROOMFIELD, Colo., May 21, 2025 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX), a world leader in innovative casual footwear for all, today announced that the organization has elevated Terence Reilly to Executive Vice President, Chief Brand Officer, with oversight over the marketing and communications functions for both the Crocs and HEYDUDE brands, effective immediately. As a veteran brand expert, Terence has a proven track record of building lasting brand identity, connecting to relevant culture and creating strategies that foster consumer engagement and loyalty. In this newly created role, Terence will be responsible for stewarding the marketing visions across both brands, elevating creative d

    5/21/25 4:30:00 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Financials

    Live finance-specific insights

    View All

    Crocs, Inc. Announces Conference Call to Review First Quarter 2026 Earnings Results

    BROOMFIELD, Colo., April 9, 2026 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX) announced today that on Thursday, April 30, 2026, at 8:30 am ET, it will host a conference call to discuss the results of its first quarter ended March 31, 2026.To receive conference call details, please register at the Investor Relations section of the Crocs website, investors.crocs.com. The webcast will also be available live and on replay through April 30, 2027 at this site.About Crocs, Inc.: Crocs, Inc. (NASDAQ:CROX), headquartered in Broomfield, Colorado, is a world leader in innovative casual footwear for all, combining comfort and style with a value that consumers know and love. The Company's brands include Cro

    4/9/26 7:30:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLK
    $CROX
    $KXIN
    $MACQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crocs Inc.

    SC 13G/A - Crocs, Inc. (0001334036) (Subject)

    11/12/24 9:55:15 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form SC 13G filed by Allakos Inc.

    SC 13G - Allakos Inc. (0001564824) (Subject)

    11/12/24 9:50:12 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care